|Download document||Draft guideline on evaluation of anticancer medicinal products in man|
|Reference number||EMA/CHMP/205/95 Rev. 5|
|Status||draft: consultation closed|
The purpose of this guideline is to provide guidance on all stages of clinical drug development for the treatment of malignancies, including drug resistance modifiers or normal tissue protective compounds. Supportive measures such as anti-emetics and haematopoietic growth factors, however, are covered by separate guidelines.